Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13480
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-16T03:20:44Z
dc.date.available2015-05-16T03:20:44Z
dc.date.issued1996-05-16en
dc.identifier.citationJournal of Cardiovascular Pharmacology; 27 Suppl 3(): S55-60en
dc.identifier.govdoc8872300en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13480en
dc.description.abstractBoth population (mass) strategies and targeted strategies for the management of high blood pressure are necessary. However, it has yet to be proven that reducing blood pressure by lifestyle changes in the population will confer the same cardiovascular benefit that results from lowering blood pressure by drugs. It is important to identify and correct those factors in hypertensive patients, such as obesity, smoking, elevated lipids, and diabetes, that confer high risk for an adverse cardiovascular event. It is now recognized that cardiovascular risk involves not only diet and lifestyle effects but that the structural and functional abnormalities resulting from high blood pressure are of great importance. There is a need to develop and validate new noninvasive methods for quantitating these structural and functional changes, together with assessment of endothelial dysfunction, hormonal profiling, and identification of susceptible genes so that high risk patients with hypertension can be selected for drug therapy. In the future, selection of an appropriate antihypertensive drug for an individual patient should also involve consideration of risk factors, structural changes, hormonal status, and genetic consideration. Central inhibition of peripheral sympathetic action by imidazoline receptor agonists, such as moxonidine, may lead to reversal of these structural and functional abnormalities without adverse effects on the central nervous system.en
dc.language.isoenen
dc.subject.otherAdrenergic alpha-Antagonists.therapeutic useen
dc.subject.otherAtrial Natriuretic Factor.physiologyen
dc.subject.otherForecastingen
dc.subject.otherGenetic Markers.physiologyen
dc.subject.otherHumansen
dc.subject.otherHypertension.drug therapy.epidemiologyen
dc.subject.otherRenin.blooden
dc.subject.otherRisk Factorsen
dc.titleFuture management of high blood pressure.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Cardiovascular Pharmacologyen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin, Australiaen
dc.description.pagesS55-60en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8872300en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.